BEHAVIORAL, INTEGRATIVE AND CLINICAL NEUROSCIENCETrilostane exerts antidepressive effects among wild-type, but not estrogen receptor β knockout miceKoonce, Carolyn J.a; Walf, Alicia A.a; Frye, Cheryl A.a b c d Author Information Departments of aPsychology bBiology cCenter for Neuroscience dCenter for Life Science Research, University at Albany-SUNY, Albany, New York, USA Correspondence to Professor Cheryl Frye, PhD, Life Sciences Room 1058, The University at Albany-SUNY, 1400 Washington Avenue, Albany, NY 12222, USA Tel: +1 518 591 8839; fax: +1 518 591 8848; e-mail: [email protected] Received 27 February 2009 accepted 9 April 2009 NeuroReport: August 5, 2009 - Volume 20 - Issue 12 - p 1047-1050 doi: 10.1097/WNR.0b013e32832e0c44 Buy Metrics Abstract Women with estrogen receptor (ER) positive breast cancer, who are treated with the ER blocker, tamoxifen, have an increased risk of depression. Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, is now being used to treat tamoxifen-insensitive breast cancer. In-vitro assays show that trilostane may have actions through ERβ. Results of in-vivo research shows that actions at ERβ may underline some antidepressant effects of estrogen. We hypothesized that trilostane may exert antidepressive effects in the forced swim in part due to actions through ERβ. Trilostane (25 mg/kg, intraperitoneally), compared with vehicle, had significant antidepressant-like effects but only when administered to wild-type, not ERβ knockout, mice. Thus, actions of trilostane through ERβ may underlie some of its antidepressant-like effects. © 2009 Lippincott Williams & Wilkins, Inc.